Menu
Search
|

Menu

Close
X

Trovagene Inc TROV.OQ (NASDAQ Stock Exchange Capital Market)

0.78 USD
+0.01 (+1.30%)
As of 8:13 PM GMT
chart
Previous Close 0.77
Open 0.77
Volume 24,984
3m Avg Volume 230,991
Today’s High 0.78
Today’s Low 0.76
52 Week High 7.66
52 Week Low 0.65
Shares Outstanding (mil) 37.27
Market Capitalization (mil) 31.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
0
FY15
0
EPS (USD)
FY18
-2.100
FY17
-9.178
FY16
-15.614
FY15
-13.051
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
89.43
5.69
Price to Book (MRQ)
vs sector
7.52
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
46.84
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-144.44
15.05
Return on Equity (TTM)
vs sector
-204.02
16.62

EXECUTIVE LEADERSHIP

Thomas Adams
Chairman of the Board, Interim Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Athena Countouriotis
Director, Since 2017
Salary: --
Bonus: --
Paul Billings
Independent Director, Since 2013
Salary: --
Bonus: --
John Brancaccio
Independent Director, Since 2005
Salary: --
Bonus: --
Gary Jacob
Independent Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

11055 Flintkote Ave
SAN DIEGO   CA   92121-1220

Phone: +1858.2175420

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.

SPONSORED STORIES